Lebovits Chaim's Form 4/A amendment
AmendedBrainstorm Cell Therapeutics Inc. (BCLI) · filed Jul 31, 2024
- Accession no.
- 0001104659-24-084334
- Filed
- Jul 31, 2024
- Trade date
- Apr 17-18, 2024
- Filing delay
- 105 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Apr 19, 2024
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $132.5K. It was filed 105 days after the trade.
This amendment replaces 0001104659-24-049027 (filed Apr 19, 2024).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lebovits ChaimCIK 0001406302 | Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 17, 2024 | Common Stock | PPurchaseAcquired | +130,000 | $0.55 | +$71,500 | 728,493 | Direct | |
| Apr 18, 2024 | Common Stock | PPurchaseAcquired | +115,072 | $0.53 | +$60,988.16 | 843,565 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.